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An objective of this research is to verify the mechanism of 
anticoagulant activity of surface-immobilized heparin in the 
presence of plasma proteins. The competition and binding 
interaction between immobilized heparin and antithrombin 
I11 (ATIII)/thrombin have been described in vituo. However, 
the strong ionic character of heparin leads to its specific and 
nonspecific binding with many other plasma proteins. 
Most notably, fibronectin contains six active binding sites 
for heparin which may interfere with the subsequent bind- 
ing of heparin with ATIII or thrombin. 
Heparin was covalently immobilized through polyethyl- 
ene oxide (PEO) hydrophilic spacer groups onto a model 
surface synthesized by random copolymerization of styrene 
and p-aminostyrene. The binding interaction of immobi- 
lized heparin with ATIII was then determined in the pres- 
ence of different fibronectin concentrations. The binding 
interaction was studied by first binding immobilized hepa- 
rin with ATIII, followed by the introduction of fibronectin; 
heparin binding with fibronectin, followed by incubation 
with ATIII, and simultaneous incubation of surface immo- 
bilized heparin with ATIII and fibronectin. The extent of 
ATIII binding to heparin in each experiment was assayed 
using a chromogenic substrate for ATIII, S-2238. 
The results of this study demonstrate that the displace- 
ment of ATIII from immobilized heparin was proportional 
to the fibronectin concentration, and was reversible. Fur- 
thermore, the binding sequence did not play a role in the 
final concentration of ATIII bound to immobilized heparin. 
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INTRODUCTION 
Heparin is a polydispersed anionic polysaccharide 
molecule with a molecular weight ranging between 
6000 and 35,000. Heparin binds and catalyzes the in- 
teraction of plasma proteins involved in the intrinsic 
and extrinsic clotting cascade, especially antithrom- 
bin I11 (ATIII). ATIII is the natural antagonist for 
thrombin, the protein which enzymatically cleaves fi- 
brinogen to form the fibrin clot. 
Rosenberg and Damus' described the overall 
mechanism by which thrombin is inactivated by 
ATIII. These investigators showed that ATIII neutral- 
izes thrombin by forming a 1:l stoichiometric com- 
plex via a reactive site (arginine)-active center (serine) 
interaction. The complex formation occurs at a rela- 
tively slow rate in the absence of heparin. However, 
heparin binds to lysine residues on ATIII, thereby 
accelerating the inhibition of thrombin. 
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Due to the high molecular weight and ionic char- 
acter of heparin, it has been studied for its binding 
interaction with other plasma Specifi- 
cally, heparin binding to plasma proteins has been 
divided into three classes, depending on the type and 
extent of binding interaction. The first class includes 
specific binding of ATIII to heparin, resulting in a 
conformational change in the protein and catalyzing 
its anticoagulant activity. The second class of binding 
interaction includes molecules such as heparin cofac- 
tor 11,4 l ip~protein,~ histidine-rich glycoprotein,6 and 
PF4.7 The binding of this group is dependent on the 
charge density of heparin and protein configuration. 
The third class of binding includes proteins such as 
fibronectin,' thrombin, and vitronectin.' This bind- 
ing interaction to heparin depends on the charge den- 
sity and the chain length of heparin. 
In previous research performed in our laboratory, 
Winterton et al. lo studied the adsorption of fibronec- 
tin, albumin, and fibrinogen onto surface-immo- 
bilized heparin. They showed that both albumin and 
fibrinogen had no binding affinity to heparin at phys- 
iological pH. However, human plasma fibronectin 
was shown to bind to solution heparin and immobi- 
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lized heparin. Furthermore, fibronectin was shown to 
have six active binding sites for heparin which may 
be sterically blocked in some adsorbed states. 
The anticoagulant action of heparin immobilized 
onto polymer surfaces using grafted hydmphilic 
spacer groups has been and the binding 
mechanisms of immobilized heparin with ATIII and 
thrombin were also delineated in v i t r ~ . ' ~ , ~ ~  However, 
since heparin (both immobilized and solution) is able 
to bind other plasma proteins, especially in vivo, stud- 
ies defining the competitive binding between ATIII 
and plasma proteins is necessary. As mentioned, fi- 
bronectin is a prominent plasma protein with specific 
binding sites for heparin, and plays a vital role in 
hemostasis. Therefore, the ability of immobilized 
heparin to bind to ATIII in the presence of fibronectin 
in vitro may help explain the anticoagulant mecha- 
nism of immobilized heparin in vim. 
EXPERIMENTAL PROCEDURES 
Heparinized surfaces 
Heparin was immobilized onto a surface via a hy- 
drophilic spacer, as shown in Figure 1. Random co- 
polymers of styrene (Aldrich Chemicals, Milwaukee, 
WI) and p-aminostyrene (Polysciences, Warrington, 
PA) were synthesized as the polymer substrate. The 
optimum composition ratio of styrene and p-ami- 
nostyrene was 74126, as defined in previous re- 
~earch . '~ , '~  The polymer substrate was then coated 
onto glass beads (100 ? 10 pm diameter, Ferro- 
Cataphote Co., Jackson, MS) for subsequent polyeth- 
ylene oxide (PEO) and heparin coupling. 
PEO was used as a hydrophilic spacer group to 
couple heparin to the polymer surface. Hydroxyl 
groups of PEO (Sigma Chemical Co., St. Louis, MO) 
(MW 3400) were modified with tolylene diisocyanate 
(TDI, Kodak, Co., Rochester, NY) to generate isocy- 
HEPARIN 
Figure 1. 
face. 
Heparin immobilization onto the polymer sur- 
anate-reactive terminal groups. PEO spacer was 
grafted onto the polymer substrate through a chem- 
ical coupling reaction between the isocyanate group 
of modified PEO spacer and the -NH, group of 
p-aminostyrene. The surface density of grafted 
spacer was determined to be 16.3 pmol/cm2, as re- 
ported in a previous ~ t u d y . ' ~ , ' ~  
Low-molecular-weight heparin (Hepar Industries, 
Inc., Franklin, OH), with a molecular weight of 6000 
and an anticlotting activity of 95 USP Ulmg (Factor 
Xa), was used in these experiments. This heparin was 
fractionated on an ATIII-affinity column to obtain 
high-ATIII-affinity heparin. Approximately 12% of 
the initial heparin concentration was isolated in the 
high-affinity fraction, resulting in an absolute activity 
of 323 USP Uimg (FXa), nearly 3.4 times the activity of 
the unfractionated 
This high ATIII affinity heparin fraction was immo- 
bilized onto the PEO spacer by a coupling reaction 
between isocyanate groups of the PEO spacer and the 
amine or hydroxyl groups of heparin. The surface 
density of immobilized heparin was 13.7 pmol/cm2, 
as cited in a previous report.I4 The binding mole ratio 
of immobilized heparin to PEO spacer was 0.91:1, 
implying that nearly one PEO group was coupled 
with one heparin m~lecule . '~  
Purification of fibronectin 
Fibronectin was isolated from human plasma by 
affinity chromatography on a gelatin-Sepharose col- 
umn at room temperature. Phenylmethysulfonylflu- 
oride (0.1 mM) was added as a protease inhibitor to 
plasma, as well as to all buffers. Tris buffer (pH 7.4) 
included 10 mM EDTA, 0.02% NaN,, 5 mM EACA 
(€-amino capric acid), and 1 mM benzamidine. 
Plasma (250 mL, Bloodbank Twente-Achterhoek, En- 
schede, The Netherlands) was centrifuged at 300 g for 
30 min. This plasma was eluted over a Sepharose 4B 
column (500 mL), and subsequently applied to a 125 
mL column of gelatin-Sepharose 4B. The gelatin- 
Sepharose 4B column was washed with 50 mM Tris- 
HC1 buffer for 3 h at a flow rate of 75 mL/h. After 
washing with 50 mM Tris-HC1 buffer overnight, the 
column was washed with 1M NaCl in 50 mM Tris- 
HC1 buffer (250 mL) to eliminate any nonspecifically 
bound fibronectin. The flow rate was 90 mL/h and the 
washing volume was 250 mL. After washing again 
with buffer for 3 hours (75 mLih), the column was 
washed with 1M urea in 50 mM Tris-HC1 buffer (250 
mL) to elute the weak-affinity fibronectin. Finally, 4h4 
urea in 50 mM Tris-HC1 buffer was eluted with 20 
mL/h flow rate. High-affinity fibronectin was eluted 
in the sixteenth through twenty-first volume (42 mL), 
based on UV absorbance at 280 nm. The fibronectin 
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solution was diluted to 0.5 mgimL, dialyzed in PBS 
(pH 7.4) at 4"C, and stored at -30°C. 
100 ~J.L concentrated acetic acid. The reaction between 
S-2238 and free thrombin was monitored by measur- 
ing the enzymatic cleavage of S-2238 to release p-ni- 
troanilide fragments (pNA, A, = 405 nm). 
Glass treatment 
Elgue et al.I5 reported that ATIII binding to heparin 
decreased by nearly 15% when the kinetic experi- 
ments were performed in plastic tubes, rather than 
siliconized glass tubes. Therefore, the glass vials used 
in subsequent kinetic experiments were treated with 
dichlorodimethylsiloxane (Kodak Co., Rochester, 
NY) to prevent nonspecific protein adsorption. Glass 
vials were soaked in 5% dichlorodimethylsiloxane in 
toluene at 25°C for 1 h, and then washed three times 
in pure ethanol, followed by washing in purified dis- 
tilled water. 
Chromogenic substrate assay for ATIII 
The concentration of ATIII in all binding experi- 
ments was determined by a two-step chromogenic 
substrate assay using S-2238 (Pharmacia/Hepar, 
Franklin, OH). The heparin-immobilized beads were 
incubated in 2 mL of the various ATIII and fibronectin 
buffer solutions. An aliquot of the sample solution 
(600 pL) was incubated with 100 pL of buffer solution 
containing heparin (3 USP UimgimL) at 37°C for 3 
min. One hundred microliters of thrombin solution (2 
IUimL) was added to the mixture and mixed for 1 
min. Then, 300 pl of S-2238 solution (25 mgi38.5 mL) 
was added. The reaction was quenched by adding 
U 
Binding of ATIII to immobilized heparin 
The interaction of ATIII with this heparinized sur- 
face has been reported.14 In these studies, 250 mg of 
polymer-PEO-heparin beads (-60 cm2) were incu- 
bated with various concentrations (0-1 pM) of ATIII 
solution. After 10 minutes (the time to obtain maxi- 
mum binding interaction), the concentration of ATIII 
was assayed and a Scatchard plot was constructed. In 
this study, the binding constant between immobi- 
lized heparin and ATIII was determined to be (Ka) 
9.58 x lo7 M '. Furthermore, nonspecific binding 
between ATIII and the control surface or heparin im- 
mobilized surface was negligible.I4 
Binding of fibronectin to heparin in ATIII solution 
Two hundred fifty (250) mg (-60 cm2) of heparin- 
immobilized beads and an ATIII concentration of 0.5 
pgimL were used in each study, while the concentra- 
tion of fibronectin was 1 pgimL and 100 pgimL. The 
binding kinetics of fibronectin to heparin in the pres- 
ence of ATIII were studied under three different con- 
ditions, as shown in Figure 2. 
In the first study, the heparinized beads were in- 
cubated in a 1-mL solution of ATIII (0.5 pgimL) for 10 
: .;..; : ., 
.': ATIII if. 
. ....... ....., : 0. .. . 
+Y 
U 
f 
Figure 2. Summary of experiments representing the sequence of ATIII and fibronectin binding to the heparinized surface. 
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min. In separate experiments, 1 mL of the 1. pgimL 
and 100-pgimL fibronectin solutions were added, and 
after 5 minutes, the solutions were sampled for the 
equilibrium ATIII solution concentration using the 
5-2238 substrate assay. Increases in ATIII from initial 
conditions implied a desorption from the immobi- 
lized heparin surface and an exchange process with 
fibronectin. 
In the second study, the heparin-immobilized 
beads were incubated in a mixed solution of ATIII 
(0.5 pgimL) and fibronectin (1 pgimL and 100 pgimL) 
for 5 min. The bulk concentration of ATIII was then 
assayed. 
Finally, fibronectin (1 pgimL and 100 pgimL) was 
incubated with heparin-immobilized beads for 5 min, 
followed by the addition of ATIII. In all cases, the 
change of ATIII in the bulk concentration was deter- 
mined. 
RESULTS AND DISCUSSION 
The ability of surface-immobilized heparin to pre- 
vent material-induced thrombus formation both in 
vitro and in vivo is well known. The main approach 
undertaken by our laboratory focused on heparin im- 
mobilization using PEO spacer groups onto a variety 
of materials. The biological activity of spacer- 
immobilized heparin has been verified, and a PEO 
chain length of 3400 daltons demonstrated optimum 
anticoagulant activity of heparin.’’ 
The current study dealing with fibronectin and 
ATIII interactions was part of a series investigating 
the interaction of spacer (PE0)-immobilized heparin 
with other proteins, including ATIII and thrombin. 
The polymer substrate (styreneip-aminostyrene) was 
used as a model surface not for its biocompatible 
properties, but for its ease of synthesis and reproduc- 
ibility. The amount of amine groups (p-aminostyrene 
content, 75:25 [Sty:p-amino Sty]) was selected based 
on experiments which demonstrated that optimum 
(-1:l) grafting of PEO groups occurred on the surface 
under these specific conditions. Thus, the amount of 
heparin groups immobilized onto the surface may not 
have been maximal in terms of other surfaces and 
other experiments, but it was optimal in the overall 
control and characterization of heparin couFling to 
PEO spacer groups (-.91:hep:PEO). Again, this par- 
ticular model surface allowed comparable amounts of 
direct immobilized heparin and  PEO spacer- 
immobilized heparin for protein binding ccmpari- 
 son^.'^,^^ 
This previous described the binding 
interaction of spacer-immobilized heparin with ATIII 
and thrombin. This research determined that PEO 
spacer-immobilized heparin binds and interacts pri- 
marily with ATIII, and has low affinity to thrombin. 
This study reported that the binding constant of ATIII 
to immobilized heparin was 9.58 X lo6 M-’,14 which 
is similar to the binding constant of solution heparin 
to ATIII (10 x 106 MP1).l6 Having this basic informa- 
tion led to initiate binding studies of other plasma 
proteins with immobilized heparin, in particular, fi- 
bronectin. 
Fibronectin is a high-molecular-weight glycopro- 
tein found in blood, other body fluids, cells, connec- 
tive tissue, and platelets, and associated with base- 
ment membranes. Fibronectins are involved in cell- 
cell adhesion, wound healing, opsonic activity, 
platelet adherence, complement activation, and acti- 
vation of the coagulation system. As mentioned, fi- 
bronectin has six ionic binding sites specific for hep- 
arin, and thus may interfere with ATIII binding to 
immobilized heparin. The binding interactions and 
competition between ATIII and fibronectin to immo- 
bilized heparin may therefore help to explain the bi- 
ological effect exhibited by this molecule. 
The AT111 concentration used in these studies of 0.5 
pgimL (-9 nM) is far below saturation conditions. 
During the ATIII binding kinetic studies,14 ATIII con- 
centrations between 0 and 1 pM were used to con- 
struct the Scatchard plots. In plasma, the concentra- 
tions of ATIII and fibronectin are 100 - 200 pgimL 
and 150 - 300 pgimL, respectively. The concentra- 
tion of ATIII in these studies was fixed at 0.5 pgimL, 
while the concentration of fibronectin was 1 and 100 
pgimL. The ATII1:fibronectin ratio of 0.5 pg/mL to 1 
pgimL represents a mid-range of the physiological 
ratio of the proteins, while the 100-pgimL fibronectin 
is far in excess. 
The binding reactions of ATIII and fibronectin to 
immobilized heparin were studied under three differ- 
ent conditions. In the first experiment (a), heparin- 
ized beads were mixed and equilibrated with ATIII, 
and then fibronectin was added to the solution. In the 
second experiment (b), both ATIII and fibronectin 
were added to the heparinized beads simultaneously. 
Finally, in the third experiment (c), AT111 was added 
to the solution after the heparinized beads were 
mixed and equilibrated with fibronectin. 
Figure 3 shows the change in the concentration of 
ATIII bound to immobilized heparin over time under 
experimental condition (a), In this study, the heparin- 
ATIII complex was formed by incubating heparin im- 
mobilized beads in 1 mL of a 0.5-pg/mL ATIII solu- 
tion. One microgram (1 pg) fibronectin was added to 
this solution and the change in bulk ATIII concentra- 
tion was measured. Using S-2238, the solution con- 
centration of ATIII did not change. In this experi- 
ment, the concentration ratio of ATIII and fibronectin 
was similar to that found in vivo (in plasma). How- 
ever, when 100 pg of fibronectin was added to the 
ATIII-bound heparin complex, -64.2% of initially 
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Figure 3. 
bound to immobilized heparin as a function of time. 
Binding interaction of fibronectin with ATIII 
bound ATIII was displaced by fibronectin from the 
binding site of immobilized heparin. This exchange 
process between two proteins on immobilized hepa- 
rin was equilibrated within 5 min. In this experiment, 
the ratio of fibronectin to ATIII concentration was 
-100 times that found in plasma. 
Figure 4 shows the desorption of bound ATIII for 
experimental condition (a) as a function of fibronectin 
concentration. At low fibronectin concentrations, 
ATIII was not displaced from heparin by fibronectin. 
However, as the fibronectin concentration increased, 
the desorption of bound ATIII increased, demonstrat- 
ing exchange between ATIII and fibronectin fcr bind- 
ing to immobilized heparin. 
Figure 5 shows the concentrations of ATIII bound 
to immobilized heparin at equilibrium when studied 
under all the experimental conditions mentioned 
CONCENTRATION OF Fn (pg/mI) 
Figure 4. Binding interaction of fibronectin with ATIII 
bound to immobilized heparin as a function of fibronectin 
concentrations. 
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Figure 5. Overall evaluation of fibronectin competing 
with ATIII for immobilized heparin as a function of incu- 
bation sequence and fibronectin concentration. 
above. Again, the concentration of ATIII was 0.5 kg/ 
mL, and the initial concentrations of fibronectin were 
chosen as 1 and 100 p.g/mL. The concentrations of 
ATIII bound to immobilized heparin under different 
conditions were nearly the same at equilibrium for all 
experimental conditions for each particular fibronec- 
tin concentration. Thus, the binding competition be- 
tween ATIII and fibronectin to immobilized heparin 
depended on the bulk protein concentration. 
CONCLUSION 
In this study, the binding interactions between an- 
tithrombin I11 and fibronectin to spacer-immobilized 
heparin was studied. Extensive research has detailed 
the binding between ATIII and immobilized heparin 
in vituo. However, in vivo contact of immobilized 
drugs may involve binding competition between sev- 
eral proteins. Therefore, the effect of protein binding 
of immobilized heparin with ATIII in the presence of 
another primary plasma protein, fibronectin, was in- 
vestigated. At protein concentrations representing 
physiological ratios, fibronectin did not displace 
bound ATIII from immobilized heparin. However, 
under excessive fibronectin concentration, ATIII was 
desorbed from heparin. This demonstrates that fi- 
bronectin can interfere with ATIII binding to heparin 
as a function of fibronectin concentration. This study 
may help extrapolate in vitro protein binding data of 
immobilized heparin to that of in vivo results. 
This work was supported by NIH grant HL 20251-18. 
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